Galapagos NV Stock Earnings Report NASDAQ:GLPG
Current P/E ratio: 0 | Price (Dec 02, 2022, EOD): $40.23 (Find current average P/E ratios for all sectors below)
GLPG Upcoming EarningsCurrently no data available.
GLPG Analysts Price TargetsCurrently no data available.
About Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Last 3 Quarters for GLPG Premium
Below you can see how GLPG performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
|Name||Number of firms||Average PE|
|Auto & Truck||13||15|
|Bank (Money Center)||7||11|
|Brokerage & Investment Banking||39||14|
|Business & Consumer Services||165||32|
|Coal & Related Energy||22||7|
|Electronics (Consumer & Office)||20||18|
|Environmental & Waste Services||82||70|
|Financial Svcs. (Non-bank & Insurance)||232||36|
|Green & Renewable Energy||22||88|
|Healthcare Support Services||128||131|
|Heathcare Information and Technology||129||132|
|Investments & Asset Management||192||120|
|Metals & Mining||92||37|
|Office Equipment & Services||22||16|
|Oil/Gas (Production and Exploration)||269||19|
|Packaging & Container||24||43|
|Publishing & Newspapers||31||28|
|Real Estate (Development)||20||146|
|Real Estate (General/Diversified)||12||31|
|Real Estate (Operations & Services)||57||23|
|Retail (Building Supply)||17||202|
|Retail (Grocery and Food)||13||38|
|Retail (Special Lines)||89||25|
|Shipbuilding & Marine||10||30|
|Software (System & Application)||363||144|
|Total Market (without financials)||5878||62|
Updated: Jan 2020
About Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The compan... GLPG Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.